<DOC>
	<DOCNO>NCT01270802</DOCNO>
	<brief_summary>Efavirenz , commonly use HIV medication , may cause worsen vascular function bone problem . The purpose study determine switch efavirenz raltegravir , new HIV medication , improve vascular function test bone health .</brief_summary>
	<brief_title>Effects Switching Efavirenz Raltegravir Vascular Function Bone Markers HIV-infected Patients</brief_title>
	<detailed_description>Cardiovascular disease ( CVD ) increasingly important comorbidity HIV-infected patient . Our preliminary data suggests efavirenz may worsen endothelial function , turn may increase risk future CVD event . Efavirenz also link low vitamin D level , may turn result increase bone fragility . Raltegravir know affect either endothelial function vitamin D level . Therefore , switch efavirenz raltegravir patient suppress HIV viremia may lead improved outcome .</detailed_description>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>HIV1 infection , document ( 1 ) license rapid HIV test HIV enzyme chemiluminescence immunoassay ( E/CIA ) test kit time prior study entry confirm licensed Western blot second antibody test method initial rapid HIV and/or E/CIA , ( 2 ) two detectable HIV1 antigen , ( 3 ) two detectable plasma HIV1 RNA viral load . Age equal great 18 year . Receipt TDF/FTC/EFV subject 's initial ART regimen least one year prior Screening . Note : Interruptions TDF/FTC/EFV 10 day total 90 day prior screen allow . Note : Subjects receive 3TC ( lamivudine ) TDF/EFV part initial regimen receive TDF/FTC/EFV least one year prior screen eligible . HIV1 RNA level &lt; 50copies/mL screen history HIV1 RNA level &lt; 50copies/mL 1 6 month prior screen . At least one genotypic resistance test do prior initiation TDF/FTC/EFV suggest evidence antiretroviral resistance nucleos ( ) ide reverse transcriptase inhibitor nonnucleoside reverse transcriptase inhibitor . No previous use raltegravir integrase inhibitor . For woman reproductive potential , negative urine pregnancy test screen willingness use two form birth control course study . Acceptable form birth control include condom ( without gel kill sperm ) , diaphragm cervical cap ( without gel kill sperm ) , intrauterine device ( IUD ) , hormonalbased birth control ( `` pill '' ) . Inability complete write , informed consent . Incarceration time study visit . Diagnosed vascular disease ( history angina pectoris , coronary disease , peripheral vascular disease , cerebrovascular disease , aortic aneurysm , otherwise know atherosclerotic disease ) . Diagnosed disease process , besides HIV infection , associate increase systemic inflammation ( include , limited , systemic lupus erythematosis , inflammatory bowel disease , collagen vascular disease ) . Note : Hepatitis B C coinfections NOT exclusionary Known suspect malignancy require systemic treatment within six month screen . History ADAdefined diabetes mellitus Note : History gestational diabetes exclusionary potential subject current ADAdefined diabetes . History migraine headache . History Raynaud 's phenomenon . History cardiac arrhythmia cardiomyopathy . Uncontrolled hyperthyroidism hypothyroidism , define TSH value outside local reference range recent clinical assessment . History hypoparathyroidism hyperparathyroidism , even treat . Known allergy intolerance nitroglycerin . History carotid bruits . Creatinine clearance &lt; 50mL/min ( use CockcroftGault equation ) use serum creatinine level measure screen . Hemoglobin &lt; 9.0mg/dL screening . Alanine aminotransferase ( ALT ) level aspartate aminotransferase ( AST ) &gt; 3 time ULN screening . Total bilirubin &gt; 2.5 time ULN screening . Fever , define T ≥ 38.0C within 48 hour prior screen . Note : Fever within 48 hour prior main study visit require postponement study visit patient defervesce ( T &lt; 38.0C ) least 48 hour ; fever continue past allow study visit timeframe result study discontinuation . Therapy acute infection serious medical illness within 14 day prior screen . Note : Therapy acute infection serious medical illness overlap main study visit result postponement study visit course therapy complete ; postponement outside allow study visit timeframe result study discontinuation . Pregnancy breastfeed course study . Hypotension , define systolic blood pressure &lt; 90mmHg , time screen . Note : Hypotension note prior brachial artery reactivity test main study visit result study visit postponement least one day systolic pressure ≥ 90mmHg morning brachial reactivity test ; postponement outside allow study visit timeframe result study discontinuation . Uncontrolled hypertension , define systolic blood pressure &gt; 160mmHg diastolic blood pressure &gt; 100mgHg screening . Receipt investigational agent , cytotoxic chemotherapy , systemic glucocorticoid ( dose ) , anabolic steroid screen . Note : Physiologic testosterone replacement therapy exclusionary . Receipt lipidlowering drug anticonvulsant ( define drug significant CYP 450 induction inhibition ) screening . Use sildenafil , vardenafil , tadalafil within 72 hour ( ) main study visit . Active drug alcohol use dependence , opinion investigator , would interfere adherence study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Endothelial function</keyword>
	<keyword>Vitamin D</keyword>
	<keyword>Efavirenz</keyword>
	<keyword>Raltegravir</keyword>
</DOC>